The company has launched its biosimilar rituximab, Ritucad, for the Indian market.
Ahmedabad, India-based Cadila Pharmaceuticals has launched Ritucad, its biosimilar product referencing Roche’s blockbuster MabThera/Rituxan (rituximab) originator biologic, for the Indian market, Cadila announced in a July 29, 2020 press release. Ritucad is used for treating blood cancer, including Non-Hodgkin’s lymphoma, and rheumatoid arthritis. Roche’s MabThera/Rituxan had nearly CHF 5 billion (US $5 billion) in 2019 sales (1).
Ritucad will be made available in a single-dose vial of two strengths, 100 mg and 500 mg. Ritucad marks the second biosimilar in a series of biosimilar products planned by Cadila in 2020. The company also recently launched Bevaro, a biosimilar referencing Roche’s top-selling Avastin (bevacizumab), a cancer-treating biologic that had CHF $7 billion (US $7.6 billion) in 2019 sales (1).
1. Roche, “Finance Report 2019,” roche.com/investors, March 2020.
Source: Cadila Pharmaceuticals
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
Teva and Samsung Bioepis Launch Biosimilar Eculizumab in US Market
April 17th 2025Eculizumab-aagh (EPYSQLI) is now available in the US to treat patients living with difficult-to-treat rare diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and generalized myasthenia gravis.